Wellforce Selects Omnicell's Medication Management Automation and Diversion Prevention Solutions
Health System that Includes Tufts Medical Center and Lowell General Hospital Increases Patient Safety and Medication Security
MOUNTAIN VIEW, Calif., Oct. 27, 2016 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL) today announced that Wellforce has selected the Company's medication management automation and analytics solutions to ensure medication security and safety at its hospitals. Wellforce, a health system founded in 2014 by Massachusetts-based Tufts Medical Center and Lowell General Hospital, is committed to innovation and leveraging new technologies to further improve patient safety while maintaining lower healthcare costs.
Automated medication management helps verify that the right patient receives the right medication at the right time, and it can also help keep hospital and patient costs down by reducing unaccounted for medications in the hospital. A recent study shows medication spending in hospitals increased by 23.4 percent annually from 2013 to 2015, making it more important than ever to ensure medications are secure in the inpatient setting.1
Both hospitals will be updating their automated medication distribution systems in the patient care areas. The goal is to improve patient safety and streamline provider workflows in the medication administration process. The facilities will also be using Omnicell Analytics, a drug diversion analytics platform that uses prescribing and medication administration data to help proactively prevent and identify drug diversion in the hospital.
"As we work together to evaluate how new solutions and technologies will support our existing and future members of the Wellforce network, patient safety will always be our central focus," said Brooke Hynes, Wellforce spokesperson. "By improving the security and safe handling of medications on our hospital floors and quickly identifying any issues, we are putting our patients first."
"We are excited about the opportunity to support Wellforce's commitment to providing excellent care at lower costs, and are inspired by the personalized level of care the system's hospitals and physicians deliver to their patients," said J. Christopher Drew, president, North American Automation and Analytics at Omnicell. "By leveraging the collaborative nature of a health system while focusing on their unique patient needs, these facilities have demonstrated that they are doing everything they can to provide the highest level of care."
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on improving care across the entire healthcare continuum—from the acute care hospital setting, to post-acute skilled nursing and long-term care facilities, to the patient's home.
Over 4,000 customers worldwide use Omnicell automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence and improve patient safety. The recent acquisition of Aesynt adds distinct capabilities, particularly in central pharmacy and IV robotics, creating the broadest medication management product portfolio in the industry.
The Omnicell SureMed solution provides innovative medication adherence packaging to help reduce costly hospital readmissions. These medication adherence solutions are used by over 17,000 institutional and retail pharmacies in North America and the United Kingdom. These pharmacies are served via the Company's sales channels and our solutions enable them to maintain high accuracy and quality standards in medication dispensing and administration while optimizing productivity and controlling costs.
For more information about Omnicell, Inc. please visit www.omnicell.com.
OMCL-G
Editor's Notes:
- All Omnicell news releases (financial, acquisitions, products, technology etc.) are issued exclusively by PR Newswire and are immediately thereafter posted on the company's external website, omnicell.com.
- Omnicell and the Omnicell logo design are registered trademarks of Omnicell, Inc.
- All other brand or product names may be trademarks or registered trademarks of their respective companies.
1 American Hospital Association (2016). Hospital Data Show Skyrocketing Drug Prices. http://www.aha.org/presscenter/pressrel/2016/161011-pr-drugpricing.shtml
Logo - http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
SOURCE Omnicell, Inc.
Share this article